Page 206 - Eceptor News Today

A new study presents the benefits of licorice, an age-old herbal remedy, to treat COVID-19 at all stages.

In the nearly 1 million Americans living with multiple sclerosis, the fatty substance that insulates the nerves of the central nervous system—called myelin—is damaged.

Scientists Dr. Cristina Puig-Saus and Dr. Daniel Shin from the UCLA Jonsson Comprehensive Cancer Center have received a $1 million Translational Research Award from the U.S. Department of Defense Melanoma Research Program to help advance the use of chimeric antigen receptor, or CAR, T cell therapy as a treatment for people with acral, mucosal and uveal melanomas.

Certain steroid-like compounds from Taiwan's endemic medicinal mushrooms (known as antcins) may inhibit a host cell receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and, thus, prevent viral infection and subsequent development of the coronavirus disease (COVID-19), reports a new study published in the MDPI's journal Plants.

The virus that causes COVID-19 today is not the same as the one that first sickened people way back in December 2019.

Since the early days of the COVID pandemic, scientists have aggressively pursued the secrets of the mechanisms that allow severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to enter and infect healthy human cells.

A team of researchers led by bioengineers at the Georgia Institute of Technology is expanding the precision and ability of a revolutionary immunotherapy that is already transforming oncology. CAR T-Cell therapy has been hailed by patients, clinical-researchers, investors, and the media as a viable cure for some cancers.

A new study reports an enhanced expression of STAT1 in mild and severely infected COVID-19 patients as compared to controls

More than 43,000 American women will die from breast cancer this year. Most of those deaths will occur after the cancer has spread to other organs, a process called metastasis. This involves at least five major steps.

A recent study conducted at the Medical University of Graz, Austria, has revealed that the number of naïve B cells in the blood could independently predict the magnitude of immune response induced by coronavirus disease 2019 (COVID-19) vaccines in immunocompromised patients. The study is currently available on the medRxiv* preprint server.